Minimal Risk Levels (MRLs)
for
Hazardous Substances
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 9604 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99 499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) (42 U.S.C. 9604(i)(2)); prepare toxicological profiles for each substance included on the priority list of hazardous substances, and to ascertain significant human exposure levels (SHELs) for hazardous substances in the environment, and the associated acute, subacute, and chronic health effects (42 U.S.C. 9604(i)(3)); and assure the initiation of a research program to fill identified data needs associated with the substances (42 U.S.C. 9604(i)(5)).
The ATSDR Minimal Risk Levels (MRLs) were developed as an initial response to the mandate. Following discussions with scientists within the Department of Health and Human Services (HHS) and the EPA, ATSDR chose to adopt a practice similar to that of the EPA's Reference Dose (RfD) and Reference Concentration (RfC) for deriving substance specific health guidance levels for non neoplastic endpoints. An MRL is an estimate of the daily human exposure to a hazardous substance that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration of exposure. These substance specific estimates, which are intended to serve as screening levels, are used by ATSDR health assessors and other responders to identify contaminants and potential health effects that may be of concern at hazardous waste sites. It is important to note that MRLs are not intended to define clean up or action levels for ATSDR or other Agencies.
The toxicological profiles include an examination, summary, and interpretation of available toxicological information and epidemiologic evaluations of a hazardous substance. During the development of toxicological profiles, MRLs are derived when ATSDR determines that reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a given route of exposure to the substance. MRLs are based on noncancer health effects only and are not based on a consideration of cancer effects. Inhalation MRLs are exposure concentrations expressed in units of parts per million (ppm) for gases and volatiles, or milligrams per cubic meter (mg/m3) for particles. Oral MRLs are expressed as daily human doses in units of milligrams per kilogram per day (mg/kg/day). Radiation MRLs are expressed as external exposures in units of millisieverts.
ATSDR uses the no observed adverse effect level/uncertainty factor (NOAEL/UF) approach to derive MRLs for hazardous substances. They are set below levels that, based on current information, might cause adverse health effects in the people most sensitive to such substance induced effects. MRLs are derived for acute (1 14 days), intermediate (>14 364 days), and chronic (365 days and longer) exposure durations, and for the oral and inhalation routes of exposure. Currently MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method suitable for this route of exposure. MRLs are generally based on the most sensitive substance-induced end point considered to be of relevance to humans. ATSDR does not use serious health effects (such as irreparable damage to the liver or kidneys, or birth defects) as a basis for establishing MRLs. Exposure to a level above the MRL does not mean that adverse health effects will occur.
MRLs are intended to serve as a screening tool to help public health professionals decide where to look more closely. They may also be viewed as a mechanism to identify those hazardous waste sites that are not expected to cause adverse health effects. Most MRLs contain some degree of uncertainty because of the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, elderly, and nutritionally or immunologically compromised) to effects of hazardous substances. ATSDR uses a conservative (i.e., protective) approach to address these uncertainties consistent with the public health principle of prevention. Although human data are preferred, MRLs often must be based on animal studies because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes that humans are more sensitive than animals to the effects of hazardous substances that certain persons may be particularly sensitive. Thus the resulting MRL may be as much as a hundredfold below levels shown to be nontoxic in laboratory animals. When adequate information is available, physiologically based pharmacokinetic (PBPK) modeling and benchmark dose (BMD) modeling have also been used as an adjunct to the NOAEL/UF approach in deriving MRLs.
Proposed MRLs undergo a rigorous review process. They are reviewed by the Health Effects/MRL Workgroup within the Division of Toxicology and Environmental Medicine; and expert panel of external peer reviewers; the agency wide MRL Workgroup, with participation from other federal agencies, including EPA; and are submitted for public comment through the toxicological profile public comment period. Each MRL is subject to change as new information becomes available concomitant with updating the toxicological profile of the substance. MRLs in the most recent toxicological profiles supersede previously published levels. To date, 141 inhalation MRLs, 230 oral MRLs and 8 external radiation MRLs have been derived. A listing of the current published MRLs by route and duration of exposure is provided as follows.
ATSDR Contact Person for MRLs:
Dr. Selene Chou
Division of Toxicology and Environmental Medicine
Agency for Toxic Substances and Disease Registry
1600 Clifton Road, Mailstop F32
Atlanta, Georgia 30333
Telephone: 770-488-3357
E-Mail: cjc3@cdc.gov
ATSDR Minimal Risk Levels (MRLs) |
||||||||
Name | Route | Duration | MRL | Factors | Endpoint | Draft/Final | Cover Date | CAS Number |
ACENAPHTHENE | Oral | Int. | 0.6 mg/kg/day | 300 | Hepatic | Final | 08/95 | 000083-32-9 |
ACETONE | Inh. | Acute | 26 ppm | 9 | Neurol. | Final | 05/94 | 000067-64-1 |
Int. | 13 ppm | 100 | Neurol. | |||||
Chr. | 13 ppm | 100 | Neurol. | |||||
Oral | Int. | 2 mg/kg/day | 100 | Hemato. | ||||
ACROLEIN | Inh. | Acute | 0.003 ppm | 100 | Resp. | Final | 08/07 | 000107-02-8 |
Int. | 0.00004 ppm | 300 | Resp. | |||||
Oral | Int. | 0.004 mg/kg/day | 100 | Gastro. | ||||
ACRYLONITRILE | Inh. | Acute | 0.1 ppm | 10 | Neurol. | Final | 12/90 | 000107-13-1 |
Oral | Acute | 0.1 mg/kg/day | 100 | Develop. | ||||
Int. | 0.01 mg/kg/day | 1000 | Repro. | |||||
Chr. | 0.04 mg/kg/day | 100 | Hemato. | |||||
ALDRIN | Oral | Acute | 0.002 mg/kg/day | 1000 | Develop. | Final | 09/02 | 000309-00-2 |
Chr. | 0.00003 mg/kg/day | 1000 | Hepatic | |||||
ALUMINUM | Oral | Int. | 1.0 mg/kg/day | 30 | Neurol. | Final | 09/08 | 007429-90-5 |
Chr. | 1.0 mg/kg/day | 90 | Neurol. | |||||
AMERICIUM | Rad. | Acute | 4 mSv | 3 | Develop. | Final | 10/04 | 007440-35-9 |
Chr. | 1 mSv/yr | 3 | Other | |||||
AMMONIA | Inh. | Acute | 1.7 ppm | 30 | Resp. | Final | 10/04 | 007664-41-7 |
Chr. | 0.1 ppm | 30 | Resp. | |||||
ANTHRACENE | Oral | Int. | 10 mg/kg/day | 100 | Hepatic | Final | 08/95 | 000120-12-7 |
ARSENIC | Oral | Acute | 0.005 mg/kg/day | 10 | Gastro. | Draft | 09/05 | 007440-38-2 |
Chr. | 0.0003 mg/kg/day | 3 | Dermal | |||||
ATRAZINE | Oral | Acute | 0.01 mg/kg/day | 100 | Body Wt. | Final | 09/03 | 001912-24-9 |
Int. | 0.003 mg/kg/day | 300 | Repro. | |||||
BARIUM, SOLUBLE SALTS | Oral | Int. | 0.2 mg/kg/day | 300 | Renal | Final | 08/07 | 007440-39-3 |
Chr. | 0.2 mg/kg/day | 300 | Renal | |||||
BENZENE | Inh. | Acute | 0.009 ppm | 300 | Immuno. | Final | 08/07 | 000071-43-2 |
Int. | 0.006 ppm | 300 | Immuno. | |||||
Chr. | 0.003 ppm | 10 | Immuno. | |||||
Oral | Chr | 0.0005 mg/kg/day | 30 | Immuno. | ||||
BERYLLIUM | Oral | Chr. | 0.002 mg/kg/day | 300 | Gastro. | Final | 09/02 | 007440-41-7 |
BIS(CHLOROMETHYL) ETHER | Inh. | Int. | 0.0003 ppm | 100 | Resp. | Final | 12/89 | 000542-88-1 |
BIS(2 CHLOROETHYL) ETHER | Inh. | Int. | 0.02 ppm | 1000 | Body Wt. | Final | 12/89 | 000111-44-4 |
BORON AND COMPOUNDS | Inh. | Acute | 0.01 mg/m3 | 30 | Resp. | Draft | 09/07 | 007440-42-8 |
Oral | Acute | 0.2 mg/kg/day | 100 | Develop. | ||||
Int. | 0.2 mg/kg/day | 66 | Develop. | |||||
BROMODICHLOROMETHANE | Oral | Acute | 0.04 mg/kg/day | 1000 | Hepatic | Final | 12/89 | 000075-27-4 |
Chr. | 0.02 mg/kg/day | 1000 | Renal | |||||
BROMOFORM | Oral | Acute | 0.7 mg/kg/day | 100 | Hepatic | Final | 09/05 | 000075-25-2 |
Int. | 0.2 mg/kg/day | 300 | Hepatic | |||||
Chr. | 0.02 mg/kg/day | 3000 | Hepatic | |||||
BROMOMETHANE | Inh. | Acute | 0.05 ppm | 100 | Neurol. | Final | 09/92 | 000074-83-9 |
Int. | 0.05 ppm | 100 | Neurol. | |||||
Chr. | 0.005 ppm | 100 | Neurol. | |||||
Oral | Int. | 0.003 mg/kg/day | 100 | Gastro. | ||||
CADMIUM | Inh. | Acute | 0.00003 mg/m3 | 300 | Resp. | Draft | 09/08 | 007440-43-9 |
Chr. | 0.00001 mg/m3 | 9 | Renal | |||||
Oral | Int. | 0.0005 mg/kg/day | 100 | Musculo. | ||||
Chr. | 0.0001 mg/kg/day | 3 | Renal
|
|||||
CARBON DISULFIDE | Inh. | Chr. | 0.3 ppm | 30 | Neurol. | Final | 08/96 | 000075-15-0 |
Oral | Acute | 0.01 mg/kg/day | 300 | Hepatic | ||||
CARBON TETRACHLORIDE | Inh. | Int. | 0.03 ppm | 30 | Hepatic | Final | 09/05 | 000056-23-5 |
Chr. | 0.03 ppm | 30 | Hepatic | |||||
Oral | Acute | 0.02 mg/kg/day | 300 | Hepatic | ||||
Int. | 0.007 mg/kg/day | 100 | Hepatic | |||||
CESIUM | Rad. | Acute | 4 mSv | 3 | Develop. | Final | 10/04 | 007440-46-2 |
Chr. | 1 mSv/yr | 3 | Other | |||||
CHLORDANE | Inh. | Int. | 0.0002 mg/m3 | 100 | Hepatic | Final | 05/94 | 000057-74-9 |
Chr. | 0.00002 mg/m3 | 1000 | Hepatic | |||||
Oral | Acute | 0.001 mg/kg/day | 1000 | Develop. | ||||
Int. | 0.0006 mg/kg/day | 100 | Hepatic | |||||
Chr. | 0.0006 mg/kg/day | 100 | Hepatic | |||||
CHLORDECONE | Oral | Acute | 0.01 mg/kg/day | 100 | Neurol. | Final | 08/95 | 000143-50-0 |
Int. | 0.0005 mg/kg/day | 100 | Renal | |||||
Chr. | 0.0005 mg/kg/day | 100 | Renal | |||||
CHLORFENVINPHOS | Oral | Acute | 0.002 mg/kg/day | 1000 | Neurol. | Final | 09/97 | 000470-90-6 |
Int. | 0.002 mg/kg/day | 1000 | Immuno. | |||||
Chr. | 0.0007 mg/kg/day | 1000 | Neurol. | |||||
CHLORINE DIOXIDE | Inh. | Int. | 0.001 ppm | 300 | Resp. | Final | 10/04 | 010049-04-4 |
CHLORITE | Oral | Int. | 0.1 mg/kg/day | 30 | Neurol. | Final | 10/04 | 007758-19-2 |
CHLOROBENZENE | Oral | Int. | 0.4 mg/kg/day | 100 | Hepatic | Final | 12/90 | 000108-90-7 |
CHLORODIBROMOMETHANE | Oral | Acute | 0.1 mg/kg/day | 300 | Hepatic | Final | 09/05 | 000124-48-1 |
Chr. | 0.09 mg/kg/day | 300 | Hepatic | |||||
CHLOROETHANE | Inh. | Acute | 15 ppm | 100 | Develop. | Final | 12/98 | 000075-00-3 |
CHLORINE | Inh. | Acute | 0.07 ppm | 3 | Resp. | Draft | 09/07 | 007782-50-5 |
Int. | 0.002 ppm | 90 | Resp. | |||||
Chr. | 0.00005 ppm | 30 | Resp. | |||||
CHLOROFORM | Inh. | Acute | 0.1 ppm | 30 | Hepatic | Final | 09/97 | 000067-66-3 |
Int. | 0.05 ppm | 300 | Hepatic | |||||
Chr. | 0.02 ppm | 100 | Hepatic | |||||
Oral | Acute | 0.3 mg/kg/day | 100 | Hepatic | ||||
Int. | 0.1 mg/kg/day | 100 | Hepatic | |||||
Chr. | 0.01 mg/kg/day | 1000 | Hepatic | |||||
CHLOROMETHANE | Inh. | Acute | 0.5 ppm | 100 | Neurol. | Final | 12/98 | 000074-87-3 |
Int. | 0.2 ppm | 300 | Hepatic | |||||
Chr. | 0.05 ppm | 1000 | Neurol. | |||||
CHLORPYRIFOS | Oral | Acute | 0.003 mg/kg/day | 10 | Neurol. | Final | 09/97 | 002921-88-2 |
Int. | 0.003 mg/kg/day | 10 | Neurol. | |||||
Chr. | 0.001 mg/kg/day | 100 | Neurol. | |||||
CHROMIUM(III) SOLUBLE PARTICULATES | Inh. | Int. | 0.0001 mg/m3 | 300 | Resp. | Draft | 09/08 | 016065-83-1 |
CHROMIUM(III) INSOL. PARTICULATES | Inh. | Int. | 0.005 mg/m3 | 90 | Resp. | Draft | 09/08 | 016065-83-1 |
CHROMIUM(VI) | Oral | Int. | 0.005 mg/kg/day | 100 | Hemato. | Draft | 09/08 | 018540-29-9 |
Chr. | 0.001 mg/kg/day | 100 | Gastro. | |||||
CHROMIUM(VI), AEROSOL MISTS | Inh. | Int. | 0.000005 mg/m3 | 100 | Resp. | Draft | 09/08 | 018540-29-9 |
Chr. | 0.000005 mg/m3 | 100 | Resp. | |||||
CHROMIUM(VI), PARTICULATES | Inh. | Int. | 0.0003 mg/m3 | 30 | Resp. | Draft | 09/08 | 018540-29-9 |
COBALT | Inh. | Chr. | 0.0001 mg/m3 | 10 | Resp. | Final | 10/04 | 007440-48-4 |
Oral | Int. | 0.01 mg/kg/day | 100 | Hemato. | ||||
Rad. | Acute | 4 mSv | 3 | Develop. | ||||
Chr. | 1 mSv/yr | 3 | Other | |||||
COPPER | Oral | Acute | 0.01 mg/kg/day | 3 | Gastro. | Final | 10/04 | 007440-50-8 |
Int. | 0.01 mg/kg/day | 3 | Gastro. | |||||
CRESOLS | Oral | Int. | 0.1 mg/kg/day | 100 | Resp. | Final | 09/08 | 001319-77-3 |
Chr. | 0.1 mg/kg/day | 1000 | Resp. | |||||
CYANIDE, SODIUM | Oral | Int. | 0.05 mg/kg/day | 100 | Repro. | Final | 07/06 | 000143-33-9 |
CYCLOTETRAMETHYLENE TETRANITRAMINE (HMX) | Oral | Acute | 0.1 mg/kg/day | 1000 | Neurol. | Final | 09/97 | 002691-41-0 |
Int. | 0.05 mg/kg/day | 1000 | Hepatic | |||||
CYCLOTRIMETHYLENETRINITRAMINE (RDX) | Oral | Acute | 0.06 mg/kg/day | 100 | Neurol. | Final | 06/95 | 000121-82-4 |
Int. | 0.03 mg/kg/day | 300 | Repro. | |||||
CYHALOTHRIN | Oral | Acute | 0.01 mg/kg/day | 100 | Gastro. | Final | 09/03 | 068085-85-8 |
Int. | 0.01 mg/kg/day | 100 | Gastro. | |||||
CYPERMETHRIN | Oral | Acute | 0.02 mg/kg/day | 100 | Neurol. | Final | 09/03 | 052315-07-8 |
DDT, P,P'- | Oral | Acute | 0.0005 mg/kg/day | 1000 | Develop. | Final | 09/02 | 000050-29-3 |
Int. | 0.0005 mg/kg/day | 100 | Hepatic | |||||
DI(2-ETHYLHEXYL)PHTHALATE | Oral | Int. | 0.1 mg/kg/day | 100 | Repro. | Final | 09/02 | 000117-81-7 |
Chr. | 0.06 mg/kg/day | 100 | Repro. | |||||
DI-N-BUTYL PHTHALATE | Oral | Acute | 0.5 mg/kg/day | 100 | Develop. | Final | 09/01 | 000084-74-2 |
DI-N-OCTYL PHTHALATE | Oral | Acute | 3 mg/kg/day | 300 | Hepatic | Final | 09/97 | 000117-84-0 |
Int. | 0.4 mg/kg/day | 100 | Hepatic | |||||
DIAZINON | Inh. | Int. | 0.01 mg/m3 | 30 | Neurol. | Final | 09/08 | 000333-41-5 |
Oral | Acute | 0.006 mg/kg/day | 100 | Neurol. | ||||
Int. | 0.002 mg/kg/day | 100 | Neurol. | |||||
Chr. | 0.0007 mg/kg/day | 100 | Neurol. | |||||
DICHLOROBENZENE, 1,2- | Oral | Acute | 0.7 mg/kg/day | 100 | Hepatic | Final | 07/06 | 000095-50-1 |
Int. | 0.6 mg/kg/day | 100 | Hepatic | |||||
Chr. | 0.3 mg/kg/day | 100 | Renal | |||||
DICHLOROBENZENE, 1,3- | Oral | Acute | 0.4 mg/kg/day | 100 | Hepatic | Final | 07/06 | 000541-73-1 |
Int. | 0.02 mg/kg/day | 100 | Endocr. | |||||
DICHLOROBENZENE, 1,4- | Inh. | Acute | 2 ppm | 10 | Ocular | Final | 07/06 | 000106-46-7 |
Int. | 0.2 ppm | 100 | Hepatic | |||||
Chr. | 0.01 ppm | 30 | Resp. | |||||
Oral | Int. | 0.07 mg/kg/day | 100 | Hepatic | ||||
Chr. | 0.07 mg/kg/day | 100 | Hepatic | |||||
DICHLORVOS | Inh. | Acute | 0.002 ppm | 100 | Neurol. | Final | 09/97 | 000062-73-7 |
Int. | 0.0003 ppm | 100 | Neurol. | |||||
Chr. | 0.00006 ppm | 100 | Neurol. | |||||
Oral | Acute | 0.004 mg/kg/day | 1000 | Neurol. | ||||
Int. | 0.003 mg/kg/day | 10 | Neurol. | |||||
Chr. | 0.0005 mg/kg/day | 100 | Neurol. | |||||
DIELDRIN | Oral | Int. | 0.0001 mg/kg/day | 100 | Neurol. | Final | 09/02 | 000060-57-1 |
Chr. | 0.00005 mg/kg/day | 100 | Hepatic | |||||
DIETHYL PHTHALATE | Oral | Acute | 7 mg/kg/day | 300 | Repro. | Final | 06/95 | 000084-66-2 |
Int. | 6 mg/kg/day | 300 | Hepatic | |||||
DIISOPROPYL METHYLPHOSPHONATE | Oral | Int. | 0.8 mg/kg/day | 100 | Hemato. | Final | 10/98 | 001445-75-6 |
(DIMP) | Chr. | 0.6 mg/kg/day | 100 | Hemato. | ||||
DIMETHYLARSINIC ACID (DMA) | Oral | Chr. | 0.02 mg/kg/day | 100 | Renal | Final | 08/07 | 000075-60-5 |
DISULFOTON | Inh. | Acute | 0.006 mg/m3 | 30 | Neurol. | Final | 08/95 | 000298-04-4 |
Int. | 0.0002 mg/m3 | 30 | Neurol. | |||||
Oral | Acute | 0.001 mg/kg/day | 100 | Neurol. | ||||
Int. | 0.00009 mg/kg/day | 100 | Develop. | |||||
Chr. | 0.00006 mg/kg/day | 1000 | Neurol. | |||||
ENDOSULFAN | Oral | Int. | 0.005 mg/kg/day | 100 | Immuno. | Final | 09/00 | 000115-29-7 |
Chr. | 0.002 mg/kg/day | 100 | Hepatic | |||||
ENDRIN | Oral | Int. | 0.002 mg/kg/day | 100 | Neurol. | Final | 08/96 | 000072-20-8 |
Chr. | 0.0003 mg/kg/day | 100 | Neurol. | |||||
ETHION | Oral | Acute | 0.002 mg/kg/day | 30 | Neurol. | Final | 09/00 | 000563-12-2 |
Int. | 0.002 mg/kg/day | 30 | Neurol. | |||||
Chr. | 0.0004 mg/kg/day | 150 | Neurol. | |||||
ETHYLBENZENE | Inh. | Acute | 10 ppm | 30 | Neurol. | Draft | 09/07 | 000100-41-4 |
Int. | 0.7 ppm | 300 | Neurol. | |||||
Chr. | 0.3 ppm | 300 | Renal | |||||
Oral | Int. | 0.5 mg/kg/day | 100 | Hepatic | ||||
ETHYLENE GLYCOL | Inh. | Acute | 2 mg/m3 | 10 | Renal | Draft | 09/07 | 000107-21-1 |
Oral | Acute | 0.8 mg/kg/day | 100 | Develop. | ||||
Int. | 0.8 mg/kg/day | 100 | Develop | |||||
ETHYLENE OXIDE | Inh. | Int. | 0.09 ppm | 100 | Renal | Final | 12/90 | 000075-21-8 |
FLUORANTHENE | Oral | Int. | 0.4 mg/kg/day | 300 | Hepatic | Final | 08/95 | 000206-44-0 |
FLUORENE | Oral | Int. | 0.4 mg/kg/day | 300 | Hepatic | Final | 08/95 | 000086-73-7 |
FLUORIDE, SODIUM | Oral | Chr. | 0.05 mg/kg/day | 3 | Musculo. | Final | 09/03 | 007681-49-4 |
FLUORINE | Inh. | Acute | 0.01 ppm | 10 | Resp. | Final | 09/03 | 007782-41-4 |
FORMALDEHYDE | Inh. | Acute | 0.04 ppm | 9 | Resp. | Final | 07/99 | 000050-00-0 |
Int. | 0.03 ppm | 30 | Resp. | |||||
Chr. | 0.008 ppm | 30 | Resp. | |||||
Oral | Int. | 0.3 mg/kg/day | 100 | Gastro. | ||||
Chr. | 0.2 mg/kg/day | 100 | Gastro. | |||||
FUEL OIL NO.2 | Inh. | Acute | 0.02 mg/m3 | 1000 | Neurol. | Final | 06/95 | 068476-30-2 |
GUTHION | Inh. | Acute | 0.02 mg/m3 | 30 | Neurol. | Final | 09/08 | 000086-50-0 |
Int. | 0.01 mg/m3 | 30 | Neurol. | |||||
Chr. | 0.01 mg/m3 | 30 | Neurol. | |||||
Oral | Acute | 0.01 mg/kg/day | 100 | Neurol. | ||||
Int. | 0.003 mg/kg/day | 100 | Neurol. | |||||
Chr. | 0.003 mg/kg/day | 100 | Neurol. | |||||
HEPTACHLOR | Oral | Acute | 0.0006 mg/kg/day | 3000 | Repro. | Final | 08/07 | 000076-44-8 |
Int. | 0.0001 mg/kg/day | 300 | Immuno. | Draft | 09/05 | |||
HEXACHLOROBENZENE | Oral | Acute | 0.008 mg/kg/day | 300 | Develop. | Final | 09/02 | 000118-74-1 |
Int. | 0.0001 mg/kg/day | 90 | Repro. | |||||
Chr. | 0.00005 mg/kg/day | 300 | Develop. | |||||
HEXACHLOROBUTADIENE | Oral | Int. | 0.0002 mg/kg/day | 1000 | Renal | Final | 05/94 | 000087-68-3 |
HEXACHLOROCYCLOHEXANE, ALPHA- | Oral | Chr. | 0.008 mg/kg/day | 100 | Hepatic | Final | 09/05 | 000319-84-6 |
HEXACHLOROCYCLOHEXANE, BETA- | Oral | Acute | 0.05 mg/kg/day | 100 | Neurol. | Final | 09/05 | 000319-85-7 |
Int. | 0.0006 mg/kg/day | 300 | Hepatic | |||||
HEXACHLOROCYCLOHEXANE, GAMMA- | Oral | Acute | 0.003 mg/kg/day | 300 | Develop. | Final | 09/05 | 000058-89-9 |
Int. | 0.00001 mg/kg/day | 1000 | Immuno. | |||||
HEXACHLOROCYCLOPENTADIENE | Inh. | Int. | 0.01 ppm | 30 | Resp. | Final | 07/99 | 000077-47-4 |
Chr. | 0.0002 ppm | 90 | Resp. | |||||
Oral | Int. | 0.1 mg/kg/day | 100 | Renal | ||||
HEXACHLOROETHANE | Inh. | Acute | 6 ppm | 30 | Neurol. | Final | 09/97 | 000067-72-1 |
Int. | 6 ppm | 30 | Neurol. | |||||
Oral | Acute | 1 mg/kg/day | 100 | Hepatic | ||||
Int. | 0.01 mg/kg/day | 100 | Hepatic | |||||
HEXAMETHYLENE DIISOCYANATE | Inh. | Int. | 0.00003 ppm | 30 | Resp. | Final | 10/98 | 000822-06-0 |
Chr. | 0.00001 ppm | 90 | Resp. | |||||
HEXANE, N- | Inh. | Chr. | 0.6 ppm | 100 | Neurol. | Final | 07/99 | 000110-54-3 |
HYDRAZINE | Inh. | Int. | 0.004 ppm | 300 | Hepatic | Final | 09/97 | 000302-01-2 |
HYDROGEN FLUORIDE | Inh. | Acute | 0.02 ppm | 30 | Resp. | Final | 09/03 | 007664-39-3 |
HYDROGEN SULFIDE | Inh. | Acute | 0.07 ppm | 27 | Resp. | Final | 07/06 | 007783-06-4 |
Int. | 0.02 ppm | 30 | Resp. | |||||
IODIDE | Oral | Acute | 0.01 mg/kg/day | 1 | Endocr. | Final | 10/04 | 007553-56-2 |
Chr. | 0.01 mg/kg/day | 1 | Endocr. | |||||
IONIZING RADIATION, N.O.S. | Rad. | Acute | 4 mSv | 3 | Neurol. | Final | 09/99 | HZ1800-45-T |
Chr. | 1 mSv/yr | 3 | Other | |||||
ISOPHORONE | Oral | Int. | 3 mg/kg/day | 100 | Other | Final | 12/89 | 000078-59-1 |
Chr. | 0.2 mg/kg/day | 1000 | Hepatic | |||||
JP-4 | Inh. | Int. | 9 mg/m3 | 300 | Hepatic | Final | 06/95 | 050815-00-4 |
JP-5/JP-8 | Inh. | Int. | 3 mg/m3 | 300 | Hepatic | Final | 10/98 | HZ0600-26-T |
JP-7 | Inh. | Chr. | 0.3 mg/m3 | 300 | Hepatic | Final | 06/95 | HZ0600-22-T |
KEROSENE | Inh. | Int. | 0.01 mg/m3 | 1000 | Hepatic | Final | 06/95 | 008008-20-6 |
MALATHION | Inh. | Acute | 0.2 mg/m3 | 100 | Neurol. | Final | 09/03 | 000121-75-5 |
Int. | 0.02 mg/m3 | 1000 | Resp. | |||||
Oral | Int. | 0.02 mg/kg/day | 10 | Neurol. | ||||
Chr. | 0.02 mg/kg/day | 100 | Neurol. | |||||
MANGANESE, RESPIRABLE | Inh. | Chr. | 0.0003 mg/m3 | 100 | Neurol. | Draft | 09/08 | 007439-96-5 |
MERCURIC CHLORIDE | Oral | Acute | 0.007 mg/kg/day | 100 | Renal | Final | 03/99 | 007487-94-7 |
Int. | 0.002 mg/kg/day | 100 | Renal | |||||
MERCURY | Inh. | Chr. | 0.0002 mg/m3 | 30 | Neurol. | Final | 03/99 | 007439-97-6 |
METHOXYCHLOR | Oral | Int. | 0.005 mg/kg/day | 1000 | Repro. | Draft | 09/00 | 000072-43-5 |
METHYL PARATHION | Oral | Int. | 0.0007 mg/kg/day | 300 | Neurol. | Final | 09/01 | 000298-00-0 |
Chr. | 0.0003 mg/kg/day | 100 | Hemato. | |||||
METHYL-T-BUTYL ETHER | Inh. | Acute | 2 ppm | 100 | Neurol. | Final | 08/96 | 001634-04-4 |
Int. | 0.7 ppm | 100 | Neurol. | |||||
Chr. | 0.7 ppm | 100 | Renal | |||||
Oral | Acute | 0.4 mg/kg/day | 100 | Neurol. | ||||
Int. | 0.3 mg/kg/day | 300 | Hepatic | |||||
METHYLENE CHLORIDE | Inh. | Acute | 0.6 ppm | 100 | Neurol. | Final | 09/00 | 000075-09-2 |
Int. | 0.3 ppm | 90 | Hepatic | |||||
Chr. | 0.3 ppm | 30 | Hepatic | |||||
Oral | Acute | 0.2 mg/kg/day | 100 | Neurol. | ||||
Chr. | 0.06 mg/kg/day | 100 | Hepatic | |||||
METHYLMERCURY | Oral | Chr. | 0.0003 mg/kg/day | 4 | Develop. | Final | 03/99 | 022967-92-6 |
MIREX | Oral | Chr. | 0.0008 mg/kg/day | 100 | Hepatic | Final | 08/95 | 002385-85-5 |
MONOMETHYLARSONIC ACID (MMA) | Oral | Int. | 0.1 mg/kg/day | 100 | Gastro. | Final | 08/07 | 000124-58-3 |
Chr. | 0.01 mg/kg/day | 100 | Renal | |||||
N-NITROSODI-N-PROPYLAMINE | Oral | Acute | 0.095 mg/kg/day | 100 | Hepatic | Final | 12/89 | 000621-64-7 |
NAPHTHALENE | Inh. | Chr. | 0.0007 ppm | 300 | Resp. | Final | 09/05 | 000091-20-3 |
Oral | Acute | 0.6 mg/kg/day | 90 | Neurol. | ||||
Int. | 0.6 mg/kg/day | 90 | Neurol. | |||||
NICKEL | Inh. | Int. | 0.0002 mg/m3 | 30 | Resp. | Final | 09/05 | 007440-02-0 |
Chr. | 0.00009 mg/m3 | 30 | Resp. | |||||
PENTACHLOROPHENOL | Oral | Acute | 0.005 mg/kg/day | 1000 | Develop. | Final | 09/01 | 000087-86-5 |
Int. | 0.001 mg/kg/day | 1000 | Repro. | |||||
Chr. | 0.001 mg/kg/day | 1000 | Endocr. | |||||
PERCHLORATES | Oral | Chr. | 0.0007 mg/kg/day | 10 | Endocr. | Final | 08/08 | 007778-74-7 |
PERMETHRIN | Oral | Acute | 0.3 mg/kg/day | 100 | Neurol. | Final | 09/03 | 052645-53-1 |
Int. | 0.2 mg/kg/day | 100 | Neurol. | |||||
PHENOL | Oral | Acute | 1 mg/kg/day | 100 | Body Wt. | Final | 09/08 | 000108-95-2 |
PHOSPHORUS, WHITE | Inh. | Acute | 0.02 mg/m3 | 30 | Resp. | Final | 09/97 | 007723-14-0 |
Oral | Int. | 0.0002 mg/kg/day | 100 | Repro. | ||||
POLYBROMINATED BIPHENYLS (PBBs) | Oral | Acute | 0.01 mg/kg/day | 100 | Endocr. | Final | 10/04 | 036355-01-8 |
POLYBROMINATED DIPHENYL ETHERS (PBDEs), LOWER BROMINATED | Inh | Int. | 0.006 mg/m3 | 90 | Endocr. | Final | 10/04 | 032534-81-9 |
Oral | Acute | 0.03 mg/kg/day | 30 | Endocr. | 032536-52-0 | |||
Int. | 0.007 mg/kg/day | 300 | Hepatic | |||||
PBDE, DECABROMINATED | Oral | Int. | 10 mg/kg/day | 100 | Develop. | Final | 10/04 | 001163-19-5 |
POLYCHLORINATED BIPHENYLS (PCBs) (Aroclor 1254) | Oral | Int. | 0.03 ug/kg/day | 300 | Neurol. | Final | 11/00 | 011097-69-1 |
Chr. | 0.02 ug/kg/day | 300 | Immuno. | |||||
PROPYLENE GLYCOL DINITRATE | Inh. | Acute | 0.003 ppm | 10 | Neurol. | Final | 06/95 | 006423-43-4 |
Int. | 0.00004 ppm | 1000 | Hemato. | |||||
Chr. | 0.00004 ppm | 1000 | Hemato. | |||||
PROPYLENE GLYCOL | Inh. | Int. | 0.009 ppm | 1000 | Resp. | Final | 09/97 | 000057-55-6 |
REFRACTORY CERAMIC FIBERS | Inh. | Chr. | 0.03 fibers/cc | 30 | Resp. | Final | 10/04 | HZ0900-26-T |
SELENIUM | Oral | Chr. | 0.005 mg/kg/day | 3 | Dermal | Final | 09/03 | 007782-49-2 |
STRONTIUM | Oral | Int. | 2 mg/kg/day | 30 | Musculo. | Final | 10/04 | 007440-24-6 |
STYRENE | Inh. | Acute | 2 ppm | 10 | Neurol. | Draft | 09/07 | 000100-42-5 |
Chr. | 0.2 ppm | 100 | Neurol. | |||||
Oral | Acute | 0.1 mg/kg/day | 1000 | Neurol. | ||||
SULFUR DIOXIDE | Inh. | Acute | 0.01 ppm | 9 | Resp. | Final | 12/98 | 007446-09-5 |
SULFUR MUSTARD | Inh. | Acute | 0.0007 mg/m3 | 30 | Ocular | Final | 09/03 | 000505-60-2 |
Int. | 0.00002 mg/m3 | 30 | Ocular | |||||
Oral | Acute | 0.5 µg/kg/day | 1000 | Develop. | ||||
Int. | 0.07 µg/kg/day | 300 | Gastro. | |||||
TETRACHLOROETHYLENE | Inh. | Acute | 0.2 ppm | 10 | Neurol. | Final | 09/97 | 000127-18-4 |
Chr. | 0.04 ppm | 100 | Neurol. | |||||
Oral | Acute | 0.05 mg/kg/day | 100 | Develop. | ||||
TIN, INORGANIC | Oral | Int. | 0.3 mg/kg/day | 100 | Hemato. | Final | 09/05 | 007440-31-5 |
TIN, DIBUTYL- | Oral | Int. | 0.005 mg/kg/day | 1000 | Immunol. | Final | 09/05 | 000683-18-1 |
TIN, TRIBUTYL- | Oral | Int. | 0.0003 mg/kg/day | 100 | Immunol. | Final | 09/05 | 000056-36-9 |
Chr. | 0.0003 mg/kg/day | 100 | Immunol. | |||||
TITANIUM TETRACHLORIDE | Inh. | Int. | 0.01 mg/m3 | 90 | Resp. | Final | 09/97 | 007550-45-0 |
Chr. | 0.0001 mg/m3 | 90 | Resp. | |||||
TOLUENE | Inh. | Acute | 1 ppm | 10 | Neurol. | Final | 09/00 | 000108-88-3 |
Chr. | 0.08 ppm | 100 | Neurol. | |||||
Oral | Acute | 0.8 mg/kg/day | 300 | Neurol. | ||||
Int. | 0.02 mg/kg/day | 300 | Neurol. | |||||
TOXAPHENE | Oral | Acute | 0.005 mg/kg/day | 1000 | Hepatic | Final | 08/96 | 008001-35-2 |
Int. | 0.001 mg/kg/day | 300 | Hepatic | |||||
TRICHLOROETHYLENE | Inh. | Acute | 2 ppm | 30 | Neurol. | Final | 09/97 | 000079-01-6 |
Int. | 0.1 ppm | 300 | Neurol. | |||||
Oral | Acute | 0.2 mg/kg/day | 300 | Develop. | ||||
URANIUM, HIGHLY SOLUBLE SALTS | Inh. | Int. | 0.0004 mg/m3 | 90 | Renal | Final | 09/99 | HZ1800-90-T |
Chr. | 0.0003 mg/m3 | 30 | Renal | |||||
Oral | Int. | 0.002 mg/kg/day | 30 | Renal | ||||
URANIUM, INSOLUBLE COMPOUNDS | Inh. | Int. | 0.008 mg/m3 | 30 | Renal | Final | 09/99 | HZ1800-92-T |
VANADIUM | Inh. | Acute | 0.0002 mg/m3 | 100 | Resp. | Final | 07/92 | 007440-62-2 |
Oral | Int. | 0.003 mg/kg/day | 100 | Renal | ||||
VINYL ACETATE | Inh. | Int. | 0.01 ppm | 100 | Resp. | Final | 07/92 | 000108-05-4 |
VINYL CHLORIDE | Inh. | Acute | 0.5 ppm | 30 | Develop. | Final | 07/06 | 000075-01-4 |
Int. | 0.03 ppm | 30 | Hepatic | |||||
Oral | Chr. | 0.003 mg/kg/day | 30 | Hepatic | ||||
XYLENES, MIXED | Inh. | Acute | 2 ppm | 30 | Neurol. | Final | 08/07 | 001330-20-7 |
Int. | 0.6 ppm | 90 | Neurol. | |||||
Chr. | 0.05 ppm | 300 | Neurol. | |||||
Oral | Acute | 1 mg/kg/day | 100 | Neurol. | ||||
Int. | 0.4 mg/kg/day | 1000 | Neurol. | |||||
Chr. | 0.2 mg/kg/day | 1000 | Neurol. | |||||
ZINC | Oral | Int. | 0.3 mg/kg/day | 3 | Hemato. | Final | 09/05 | 007440-66-6 |
Chr. | 0.3 mg/kg/day | 3 | Hemato. | |||||
1-METHYLNAPHTHALENE | Oral | Chr. | 0.07 mg/kg/day | 1000 | Resp. | Final | 09/05 | 000090-12-0 |
2-METHYLNAPHTHALENE | Oral | Chr. | 0.04 mg/kg/day | 100 | Resp. | Final | 09/05 | 000091-57-6 |
1,1-DICHLOROETHENE | Inh. | Int. | 0.02 ppm | 100 | Hepatic | Final | 05/94 | 000075-35-4 |
Oral | Chr. | 0.009 mg/kg/day | 1000 | Hepatic | ||||
1,1-DIMETHYLHYDRAZINE | Inh. | Int. | 0.0002 ppm | 300 | Hepatic | Final | 09/97 | 000057-14-7 |
1,1,1-TRICHLOROETHANE | Inh. | Acute | 2 ppm | 100 | Neurol. | Final | 07/06 | 000071-55-6 |
Int. | 0.7 ppm | 100 | Neurol. | |||||
Oral | Int. | 20 mg/kg/day | 100 | Body Wt. | ||||
1,1,2-TRICHLOROETHANE | Oral | Acute | 0.3 mg/kg/day | 100 | Neurol. | Final | 12/89 | 000079-00-5 |
Int. | 0.04 mg/kg/day | 100 | Hepatic | |||||
1,1,2,2-TETRACHLOROETHANE | Oral | Int. | 0.5 mg/kg/day | 100 | Hepatic | Final | 09/08 | 000079-34-5 |
1,2-DIBROMO-3-CHLOROPROPANE | Inh. | Int. | 0.0002 ppm | 100 | Repro. | Final | 09/92 | 000096-12-8 |
Oral | Int. | 0.002 mg/kg/day | 1000 | Repro. | ||||
1,2-DICHLOROETHANE | Inh. | Chr. | 0.6 ppm | 90 | Hepatic | Final | 09/01 | 000107-06-2 |
Oral | Int. | 0.2 mg/kg/day | 300 | Renal | ||||
1,2-DICHLOROETHENE, CIS- | Oral | Acute | 1 mg/kg/day | 100 | Hemato. | Final | 08/96 | 000156-59-2 |
Int. | 0.3 mg/kg/day | 100 | Hemato. | |||||
1,2-DICHLOROETHENE, TRANS- | Inh. | Acute | 0.2 ppm | 1000 | Hepatic | Final | 08/96 | 000156-60-5 |
Int. | 0.2 ppm | 1000 | Hepatic | |||||
Oral | Int. | 0.2 mg/kg/day | 100 | Hepatic | ||||
1,2-DICHLOROPROPANE | Inh. | Acute | 0.05 ppm | 1000 | Resp. | Final | 12/89 | 000078-87-5 |
Int. | 0.007 ppm | 1000 | Resp. | |||||
Oral | Acute | 0.1 mg/kg/day | 1000 | Neurol. | ||||
Int. | 0.07 mg/kg/day | 1000 | Hemato. | |||||
Chr. | 0.09 mg/kg/day | 1000 | Hepatic | |||||
1,2-DIMETHYLHYDRAZINE | Oral | Int. | 0.0008 mg/kg/day | 1000 | Hepatic | Final | 09/97 | 000540-73-8 |
1,2,3-TRICHLOROPROPANE | Inh. | Acute | 0.0003 ppm | 100 | Resp. | Final | 09/92 | 000096-18-4 |
Oral | Int. | 0.06 mg/kg/day | 100 | Hepatic | ||||
1,3-DICHLOROPROPENE | Inh. | Int. | 0.008 ppm | 30 | Resp. | Final | 09/08 | 000542-75-6 |
Chr. | 0.007 ppm | 30 | Resp. | |||||
Oral | Int. | 0.04 mg/kg/day | 100 | Gastro. | ||||
Chr. | 0.03 mg/kg/day | 100 | Gastro. | |||||
1,3-DINITROBENZENE | Oral | Acute | 0.008 mg/kg/day | 100 | Repro. | Final | 06/95 | 000099-65-0 |
Int. | 0.0005 mg/kg/day | 1000 | Hemato. | |||||
1,4-DIOXANE | Inh. | Acute | 2 ppm | 10 | Ocular | Final | 07/06 | 000123-91-1 |
Int. | 1 ppm | 30 | Hepatic | |||||
Chr. | 1 ppm | 30 | Hepatic | |||||
Oral | Acute | 4 mg/kg/day | 100 | Resp. | ||||
Int. | 0.6 mg/kg/day | 100 | Hepatic | |||||
Chr. | 0.1 mg/kg/day | 100 | Hepatic | |||||
2-BUTOXYETHANOL | Inh. | Acute | 6 ppm | 9 | Hemato. | Final | 10/98 | 000111-76-2 |
Int. | 3 ppm | 9 | Hemato. | |||||
Chr. | 0.2 ppm | 3 | Hemato. | |||||
Oral | Acute | 0.4 mg/kg/day | 90 | Hemato. | ||||
Int. | 0.07 mg/kg/day | 1000 | Hepatic | |||||
2,3-DICHLOROPROPENE | Inh. | Acute | 0.002 ppm | 90 | Resp. | Final | 09/08 | 000078-88-6 |
2,3,4,7,8-PENTACHLORODIBENZOFURAN | Oral | Acute | 0.001 ug/kg/day | 3000 | Immuno. | Final | 05/94 | 057117-31-4 |
Int. | 0.00003 ug/kg/day | 3000 | Hepatic | |||||
2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN | Oral | Acute | 0.0002 ug/kg/day | 21 | Immuno. | Final | 12/98 | 001746-01-6 |
Int. | 0.00002 ug/kg/day | 30 | Lymphor. | |||||
Chr. | 0.000001 ug/kg/day | 90 | Develop. | |||||
2,4-DICHLOROPHENOL | Oral | Int. | 0.003 mg/kg/day | 100 | Immuno. | Final | 07/99 | 000120-83-2 |
2,4-DINITROPHENOL | Oral | Acute | 0.01 mg/kg/day | 100 | Body Wt. | Final | 08/95 | 000051-28-5 |
2,4-DINITROTOLUENE | Oral | Acute | 0.05 mg/kg/day | 100 | Neurol. | Final | 12/98 | 000121-14-2 |
Chr. | 0.002 mg/kg/day | 100 | Hemato. | |||||
2,4,6-TRINITROTOLUENE | Oral | Int. | 0.0005 mg/kg/day | 1000 | Hepatic | Final | 06/95 | 000118-96-7 |
2,6-DINITROTOLUENE | Oral | Int. | 0.004 mg/kg/day | 1000 | Hemato. | Final | 12/98 | 000606-20-2 |
4-CHLOROPHENOL | Oral | Acute | 0.01 mg/kg/day | 100 | Hepatic | Final | 07/99 | 000106-48-9 |
4,4'-METHYLENEBIS(2-CHLOROANILINE) | Oral | Chr. | 0.003 mg/kg/day | 3000 | Hepatic | Final | 05/94 | 000101-14-4 |
4,4'-METHYLENEDIANILINE | Oral | Acute | 0.2 mg/kg/day | 300 | Hepatic | Final | 10/98 | 000101-77-9 |
Int. | 0.08 mg/kg/day | 100 | Hepatic | |||||
4,6-DINITRO-O-CRESOL | Oral | Acute | 0.004 mg/kg/day | 100 | Neurol. | Final | 08/95 | 000534-52-1 |
Int. | 0.004 mg/kg/day | 100 | Neurol. |